Drug Profile
Research programme: protein-protein interaction blockers - Compugen
Alternative Names: CGEN-25068Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Compugen
- Class Peptides
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Immunological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in Israel (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Israel (Parenteral)
- 08 Mar 2011 Early research in Cancer in Israel (Parenteral)